India, June 9 -- NewAmsterdam Pharma Company N.V. (NAMS), a late-stage, clinical biopharmaceutical company, announced positive topline data from prespecified Alzheimer's Disease (AD) biomarker analyses in the Phase 3 BROADWAY clinical trial (NCT05142722).
The pivotal Phase 3 BROADWAY study was primarily designed to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
As part of this pivotal registration trial for lowering LDL-C, a pre-specified sub-study was condu...